Sulfagenix Inc. leverages the R&D Tax Incentive in Australia
Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise […]
了解更多
Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise […]
了解更多
Over the last three years, The George Institute’s Associate Professor Zhang Puhong has led a very important and significant study on Type 2 diabetes in China, the ORBIT (Observational Registry for Basal Insulin Treatment) study. Professor Ji Linong, the chief physician of the department of endocrinology in Peking University People’s hospital, was the principal investigator. […]
了解更多
New legislation has taken into effect which simplifies the Hong Kong regulatory process for clinical trial application in that country
了解更多
Chronic obstructive pulmonary disorder (COPD) is now the third most frequent cause of death in the world; however the cause of this disease for a substantial proportion of patients remains unknown.
了解更多
Recently, 乔治临床( George Clinical )’s Project Operations team in Australia volunteered at an OzHarvest program […]
了解更多
乔治临床( George Clinical ) provides clinical trial management services in Korea through our partner – LSK Global Pharma Services […]
了解更多
All clinical trial management comes with its challenges and we’re proud of how our team in Malaysia has handled those presented to them […]
了解更多
乔治临床( George Clinical ) has expanded its coverage in Asia to include Japan. […]
了解更多
Dr Marisa Petersen has been appointed Executive Director of 乔治临床( George Clinical ) […]
了解更多
